Forxiga cardiovascular outcomes benefit approved in China
Update to approval includes DECLARE-TIMI 58 Phase III trial that reduced the risk of composite of hospitalisation for heart failure or cardiovascular death in type-2 diabetesChina’s National Medical Products Administration (NMPA) has updated the label for AstraZeneca’s Forxiga (dapagliflozin) to include data from the DECLARE-TIMI 58 Phase III trial. DECLARE-TIMI 58